Nectar Lifesciences Limited (NECLIFE)
ISIN: - Industry: Drug Manufacturers—Specialty & Generic Sector: Healthcare Website
24.35
1.3(5.64%)

Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company offers contract research and manufacturing services, including process development and optimization, process scale up and validation, preparation and international submission of drug master files and certificates of suitability, multi kilo pilot plant production, bulk production, and chiral resolution; and chemical and analytical development, as well as analytical, manufacturing, and engineering consulting services. Its active pharmaceutical ingredients and intermediates comprise cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil, cefdinir, ceftriaxone sodium, cefotaxime sodium, cefuroxime sodium, ceftazidime, cefepime HCl, cephalothin, cefazolin sodium, cefprozil, cefoperzone sodium, cefpirome sulphate, and cefoxitin sodium. The company also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, it provides a range of diagnostics products; empty hard gelatin capsules; and menthol products. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.

Pricing Updates

TODAY'S HIGH

24.6

TODAY'S LOW

23.35

52 WEEK HIGH

47.9

52 WEEK LOW

20.75

Major Holders

% of Shares Held by
All Insider

57.04%

% of Shares Held by
Institutions

0.00%

% of Float Held by
Institutions

0.00%

Number of Institutions
Holding Shares

0

Company Overview

MARKET CAP

546.07 Cr.

ETERPRISE VALUE

1358.50 Cr.

NO. OF SHARES

22.42 Cr.

BOOK VALUE

48.517

DIV. YIELD

0.05%

DEBT

859.92 Cr.

GROSS PROFIT

445.70 Cr.

CASH

18.26 Cr.

REVENUE

1668.83 Cr.

REVENUE/SHARE

74.624

OHLC Chart 1y 2y 5y 10y

Price Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Volumes Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Cashflows

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Investments0-25 Lakhs41.40 Lakhs41.40 Lakhs
Change To Liabilities0000
Total cashflows from Investing Activities16.64 Cr.-28.62 Cr.-33.12 Cr.-26.13 Cr.
Net Borrowings-50.56 Cr.124.64 Cr.-124.68 Cr.-51.60 Cr.
Total Cash from Financing Activities-119.37 Cr.11.49 Cr.-251.86 Cr.-201.08 Cr.
Other Liabilities-64.54 Cr.-40.54 Cr.70.36 Cr.-13.19 Cr.
Total Assets0000
Net Income25.04 Cr.-73.26 Cr.31.78 Cr.47.60 Cr.
Change in Cash-7.73 Cr.4.24 Cr.-3.40 Lakhs12.01 Cr.
Effect of Exchange Rate0000
Total Cash from Operating Activities95 Cr.21.37 Cr.284.96 Cr.239.23 Cr.
Depreciation56.96 Cr.60.25 Cr.60.76 Cr.63.25 Cr.
Other Cashflows from Investing Activities1.88 Cr.2.68 Cr.2.70 Cr.9.57 Cr.
Dividends Paid0-1.12 Cr.-1.12 Cr.-1.35 Cr.
Change to Inventory0000
Change to Account Receivables0000
Other Cashflows from Financing Activities-68.81 Cr.-112.03 Cr.-126.05 Cr.-148.13 Cr.
Change to Net Income77.53 Cr.74.93 Cr.122.04 Cr.141.57 Cr.
Capital Expenditures-24.97 Cr.-31.24 Cr.-54.76 Cr.-38.12 Cr.

Financials

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Research DevelopmentNoneNoneNoneNone
Effect of Accounting ChargesNoneNoneNoneNone
Income Before Tax34.08 Cr.-84.76 Cr.37.47 Cr.58.82 Cr.
Minority InterestNoneNoneNoneNone
Net Income101.59 Cr.49.99 Cr.159.33 Cr.201.22 Cr.
Selling General Administrative74.54 Cr.75.15 Cr.82.81 Cr.81.20 Cr.
Gross Profit445.70 Cr.386.21 Cr.507.79 Cr.565.18 Cr.
Ebit101.59 Cr.49.99 Cr.159.33 Cr.201.22 Cr.
Operating Income101.59 Cr.49.99 Cr.159.33 Cr.201.22 Cr.
Other Operating Expenses212.58 Cr.188.79 Cr.204.88 Cr.219.49 Cr.
Interest Expense-78.81 Cr.-85.76 Cr.-91.80 Cr.-87.82 Cr.
Extraordinary ItemsNoneNoneNoneNone
Non RecurringNoneNoneNoneNone
Other ItemsNoneNoneNoneNone
Income Tax Expense9.03 Cr.-11.50 Cr.5.68 Cr.11.22 Cr.
Total Revenue1668.83 Cr.1543.32 Cr.2366.40 Cr.2782.89 Cr.
Total Operating Expenses1567.23 Cr.1493.33 Cr.2207.07 Cr.2581.66 Cr.
Cost of Revenue1223.13 Cr.1157.11 Cr.1858.60 Cr.2217.70 Cr.
Total Other Income Expense Net-67.51 Cr.-134.75 Cr.-121.86 Cr.-142.40 Cr.
Discontinued OperationsNoneNoneNoneNone
Net Income from Continuous Ops.25.04 Cr.-73.26 Cr.31.78 Cr.47.60 Cr.
Net Income Applicable to Common Shares25.04 Cr.-73.26 Cr.31.78 Cr.47.60 Cr.

Balance Sheet

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Intangible Assets43.02 Cr.38.36 Cr.39.19 Cr.39.18 Cr.
Capital Surplus0328.79 Cr.328.79 Cr.328.79 Cr.
Total Liabilities1302.92 Cr.1409.08 Cr.1497.18 Cr.1599.82 Cr.
Stock Holder Equity1087.90 Cr.1062.03 Cr.1136.12 Cr.1105.16 Cr.
Minority Interest0000
Other Liabilities56.63 Cr.55.65 Cr.52.94 Cr.66.44 Cr.
Total Assets2390.83 Cr.2471.11 Cr.2633.30 Cr.2704.98 Cr.
Common Stock22.42 Cr.22.42 Cr.22.42 Cr.22.42 Cr.
Retained Earnings0710.80 Cr.784.90 Cr.753.93 Cr.
Other Liabilities8.01 Cr.93.45 Cr.127.81 Cr.134.33 Cr.
Good Will0000
Treasury Stock1065.47 Cr.000
Other Assets227.55 Cr.361.53 Cr.118.06 Cr.111.32 Cr.
Cash17.80 Cr.25.53 Cr.21.29 Cr.21.32 Cr.
Current Liabilities1003.83 Cr.1187.39 Cr.1247.89 Cr.1299.90 Cr.
Long Term Asset Charges2.80 Cr.000
Short Long Term Debt568.85 Cr.63.16 Cr.37.56 Cr.101.89 Cr.
Other Stockholder Equity1065.47 Cr.000
Property Plant Equipment765.17 Cr.832.15 Cr.860.65 Cr.885.18 Cr.
Total Cur. Assets1354.84 Cr.1238.82 Cr.1615.15 Cr.1669.03 Cr.
Long Term Investments23.51 Lakhs23.50 Lakhs23.50 Lakhs27 Lakhs
Net Tangible Assets1044.88 Cr.1023.66 Cr.1096.93 Cr.1065.97 Cr.
Short Term Investments45.96 Lakhs45.70 Lakhs16.60 Lakhs50.50 Lakhs
Net Receivables447.37 Cr.421.61 Cr.457.60 Cr.618.11 Cr.
Long Term Debt291.07 Cr.128.23 Cr.121.48 Cr.165.59 Cr.
Inventory659.85 Cr.655.32 Cr.1008.08 Cr.917.97 Cr.
Accounts Payable376.65 Cr.342.15 Cr.527.14 Cr.483.67 Cr.

New Offers


Upstox offer
Upstox

Open a demat account through us and get the account opening charges waived off

open paperless account